TransCode TherapeuticsRNAZ
NASDAQPharmaceuticals
No cached AI snapshot yet for RNAZ.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
12 employees916,968.00 shares outstandinglisted 2021-07-09
Next earnings ~May 5, 2026
About TransCode Therapeutics
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
Latest News
Showing market-wide stock news
Bitcoin retreats after crypto bill setback, Fed next
This BlackRock strategist opposes a Fed hike. Here are the funds she recommends.
Gold outlook hinges on Fed signals; metal could test $4,200: Kotak Sec
US Dollar: Higher yields and oil support – MUFG
Bond Investors Are on Edge. Here's Why Stock Investors Should Pay Attention.
Wall St futures edge higher in countdown to Fed decision
Related Stocksin Pharmaceuticals
Ready to see the live AI view on RNAZ?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing RNAZ side-by-side with live signals.